The Smartest Investors Club
  • Business
  • Politics
  • Investing
  • World
  • Business
  • Politics
  • Investing
  • World

The Smartest Investors Club

Investing

CLEO Appoints CRO to Manage U.S. Ovarian Cancer Clinical Trials

by April 12, 2024
April 12, 2024
CLEO Appoints CRO to Manage U.S. Ovarian Cancer Clinical Trials

Ovarian cancer diagnostics company, Cleo Diagnostics Limited (ASX:COV) (CLEO, or the Company) is pleased to announce the appointment of international Contract Research Organization (CRO), Lindus Health, as a key partner for its U.S. clinical trials program.

Highlights

CLEO has appointed U.S.-based Lindus Health to manage U.S. clinical trials for its revolutionary ovarian cancer blood testLindus Health is a leader in clinical trial management for the med-tech sector, with a strong record of timely and successful trial executionCLEO’s U.S. study will prospectively recruit up to 500 patients commencing next month and will verify the performance of CLEO’s pre-surgical ovarian cancer test for FDA regulatory approval.

U.S. Ovarian Cancer Clinical Trials

As a part of CLEO’s U.S. market access program, the Company will partner with U.S.-based CRO, Lindus Health, appointing it to manage the successful execution of its ovarian cancer U.S. clinical trials. Lindus Health was chosen following a robust process to identify a partner with the proven experience, technology and high standards capable of delivering on CLEO’s objectives.

Lindus Health specialises in collaborating with med-tech companies to conduct clinical trials worldwide, leveraging their innovative patient recruitment and trial management technology platform to deliver efficient and timely outcomes.

Comprehensive U.S. patient data is essential for a successful regulatory application through the Food and Drug Administration (FDA). CLEO will leverage Lindus Health’s expertise to execute a cost-effective and rapid clinical study that will support its subsequent FDA 510(k) application.

The study will benchmark CLEO’s pre-surgical ovarian cancer triage test and provide the core data requirements for the FDA 510(k) application. Up to 500 U.S.-based patients will be recruited, with the trial scheduled over 10 months following ethic approvals and site engagement.

An Australian arm of the trial will also run concurrently and be managed directly by CLEO. This dual- arm strategy mitigates risk to the timelines due to patient recruitment, and will provide additional patient samples for kit verification following manufacture.

The study data will be published in the mainstream medical literature as a part of CLEO’s rigorous publication strategy.

Commenting on the partnership with Lindus Health, CLEO Chief Executive, Richard Allman, said:

“With the appointment of Lindus Health, our U.S. market access program is well underway to achieve our goal of obtaining regulatory approval for CLEO’s initial pre-surgical market in the U.S. for our ovarian cancer blood test.

CLEO is appointing high calibre partners that we believe will help us deliver our important ovarian cancer detection technology to improve the health outcomes for women.”

Click here for the full ASX Release

This post appeared first on investingnews.com
0
FacebookTwitterGoogle +Pinterest
previous post
Lancaster Resources Acquires Piney Lake Gold Property
next post
Carbon Done Right Announces Brokered Private Placement

You may also like

Lithium Universe

Crypto Market Recap: Grayscale Debuts New Bitcoin Product,...

Eric Sprott Announces Changes to His Holdings in...

Sarama Announces Equity Placement of Up to A$2M...

World Copper Establishes At-The-Market Equity Program

11 Canadian Cryptocurrency ETFs (Updated 2023)

Skyharbour Partner Company Terra Clean Energy Plans Summer...

NorthStar Gaming Announces Short-Term Financing

FDA Finds Kratom Capsules Safe, but Questions About...

Closing the Lithium Conversion Gap in North America

    Get free access to all of the retirement secrets and income strategies from our experts! or Join The Exclusive Subscription Today And Get the Premium Articles Acess for Free


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Latest

    • ‘A fear campaign.’ Students around the world are shocked, scared and saddened...

    • North Korea deploys mystery balloon-like objects to stricken warship, satellite photos show

    • NVIDIA Rallies After Strong Q1, AI Demand Outshines China Export Hit

    • US senators meet with Zelensky in Kyiv as doubt cast over upcoming Ukraine-Russia peace talks

    • Israel’s plan to ‘conquer’ Gaza is leaving Palestinians with little place to go: 5 maps show how

    Categories

    • Business (1,673)
    • Investing (4,999)
    • Politics (7,837)
    • World (6,349)
    • Terms & Conditions
    • Privacy Policy
    • About us

    Disclaimer: thesmartestinvestorsclub.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2024 thesmartestinvestorsclub.com | All Rights Reserved


    Back To Top